Summary
A longitudinal analysis of 188 countries from 2000 to 2023 found that Hib and pneumococcal conjugate vaccine introduction was associated with lower meningitis disability-adjusted life-year rates. The largest reported association was in the African meningitis belt, although the study describes the results as population-level vaccine-associated changes rather than strictly causal effects.
A longitudinal study covering 188 countries reports that the introduction of Haemophilus influenzae type b (Hib) and pneumococcal conjugate vaccines (PCV) was associated with falling population-level meningitis burden between 2000 and 2023. The largest association was reported for PCV introduction in the African meningitis belt, where meningitis disability-adjusted life-year rates were 16.8% lower after accounting for the study's statistical adjustments.
The analysis is presented in a medRxiv preprint posted on September 15, 2026. It has not been described in the supplied source as a completed peer-reviewed journal publication.
What the analysis measured
The researchers conducted a longitudinal ecological panel study using meningitis health metrics from the Global Burden of Disease study and vaccine data from the World Health Organization. The country-level analysis used two-way fixed-effects regression models, which compare changes over time while accounting for differences between countries and common time-related effects. The models were adjusted for gross domestic product and healthcare access, and the analysis was stratified by countries' baseline meningitis burden.
The main outcome was the meningitis disability-adjusted life-year, or DALY, rate. A DALY combines years of healthy life lost because of premature death with years lived with disability, allowing disease burden to be compared across populations and over time. It is a population measure rather than a record of individual patients' outcomes.
Across the countries included, meningitis DALY rates declined by 4.97% per year during the study period, with a reported p-value below 0.0001. The study associated Hib vaccine introduction with a 6.7% reduction in DALY rates and PCV introduction with a 4.8% reduction at the global level.
Benefits were concentrated in higher-burden settings
The reported associations were larger in countries with a high baseline meningitis burden. Hib and PCV introduction were each associated with reductions of about 10% in these settings, while the analysis found no statistically significant effects in low-burden countries.
In the African meningitis belt, PCV introduction was associated with a 16.8% reduction in meningitis DALY rates, with a p-value below 0.0001. The source describes this region as a high-burden setting in which vaccine deployment could produce a particularly large population-level effect.
The analysis found no significant global association between meningococcal vaccine introduction and meningitis DALY rates. This result concerns the study's country-level statistical association and does not provide an estimate of protection for an individual vaccinated person.
The researchers interpret the overall findings as evidence that global reductions in meningitis burden have been strongly associated with Hib and PCV scale-up, particularly in countries carrying the greatest burden. The study also reports pre-treatment trends for Hib. Because those trends were present before the measured vaccine-related change, the authors characterise their estimates as vaccine-associated population-level changes rather than strictly causal effects.
The work used publicly available, de-identified secondary data and did not enrol or follow individual patients. Its main implication is for population planning: vaccine deployment in endemic, high-burden regions may offer the greatest potential public-health benefit according to the study's estimates.